InsulinReceptorR抗体;InsulinReceptorR Antibody—艾普蒂

The insulin receptor (IR) is a transmembrane tyrosine kinase receptor critical for regulating glucose metabolism, cell growth, and differentiation. Composed of two extracellular α-subunits (ligand-binding domains) and two transmembrane β-subunits (tyrosine kinase signaling domains), it binds insulin to activate downstream pathways like PI3K-AKT and MAPK. Antibodies targeting the insulin receptor (IRAbs) are primarily studied in two contexts: autoimmune disorders and research tools. In autoimmune diseases such as type B insulin resistance syndrome, IRAbs act as antagonists, blocking insulin binding and causing severe insulin resistance, hyperglycemia, or hypoglycemia. These autoantibodies are often detected via immunoassays in patient sera. In research, synthetic anti-IR antibodies are widely used to investigate receptor structure, localization, and signaling mechanisms. Monoclonal antibodies (e.g., agonist mimics) help dissect insulin-independent activation pathways. Additionally, IR-targeting therapeutic antibodies are being explored for diabetes or cancer, though clinical applications remain limited. Their dual role as pathogenic agents and experimental tools underscores the IR's complexity in both physiology and disease.